Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;41(5):542-544.
doi: 10.5114/ada.2024.144405. Epub 2024 Oct 23.

Adult-onset atopic dermatitis induced by vedolizumab: a case series

Eleonora Nucera  1 , Sara Urbani  1 , Arianna Aruanno  1 , Franco Scaldaferri  2 , Dario D'Urso  3 , Clara De Simone  3
Affiliations

Adult-onset atopic dermatitis induced by vedolizumab: a case series

Eleonora Nucera et al. Postepy Dermatol Alergol. 2024 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Clinical presentation of the patient (case 3) with symmetrically distributed erythematous papules and plaques on the flexor surfaces of limbs associated with cutaneous xerosis and pruritus
See this image and copyright information in PMC

References

    1. Soler D, Chapman T, Yang LL, et al. . The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330: 864-75. - PubMed
    1. Sandborn WJ, Feagan BG, Rutgeerts P, et al. . Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-21. - PubMed
    1. Chaparro M, Garre A, Ricart E, et al. .; GETECCU study group . Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2018; 48: 839-51. - PubMed
    1. Colombel JF, Sands BE, Rutgeerts P, et al. . The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66: 839-51. - PMC - PubMed
    1. Tofte SJ, Graeber M, Cherill R, et al. . Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11: S197. - PubMed